Loading…
Maker of implantable collamer lenses (ICLs), a surgical alternative to LASIK for correcting vision, especially in myopia.
Maker of implantable collamer lenses (ICLs), a surgical alternative to LASIK for correcting vision, especially in myopia.
The lens is a one-time implant per eye, so sales depend on bringing in new patients through surgeon training and consumer demand rather than repeat purchases. China is its largest market, where patients pay privately, so economic sentiment and local competition matter.
Moat: narrow (IP / patents, brand, regulatory licence). Proprietary Collamer lens material and long track record differentiate ICL from newer competitors.
Headquarters: Lake Forest, California · Founded: 1982 · Employees: 957
Size STAAR Surgical (STAA) is a United States Health Care company (Medical Specialties) with a market value of $1.26B, the 2105th largest of 3,117 United States companies the cockpit tracks. Shares closed at $25.21 on 6 Nov 2026.
Performance Over six months the shares fell 5.5%, against -4.5% for the median peer and -1.1% for the United States market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 51.3% over the last twelve months (peer median +14.5%); the operating margin is 18.0% (peer median 15.3%).
Valuation It trades at 45.8× forward earnings against a peer median of 26.1× (3rd most expensive of 15).
Capital Return on invested capital runs 11.1 points above its cost of capital (10.8% WACC).
Short interest Short interest is 7.4% of the free float (15 Oct 2026).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $340M | $239M | $314M | $322M | $284M |
| Revenue growth | — | -24% | -3% | +13% | — |
| Gross profit | $254M | $177M | $235M | $253M | $223M |
| EBITDA | $70.8M | -$37.2M | -$5.72M | $33.2M | $48.3M |
| Net income | $3.84M | -$80.4M | -$20.2M | $21.3M | $39.7M |
| Free cash flow | -$6.75M | -$40.0M | -$7.67M | -$3.59M | $17.6M |
| Capital expenditure | $3.50M | $5.82M | $23.4M | $18.2M | $18.1M |
| Total debt | $35.9M | $38.4M | $38.7M | $35.8M | $31.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| STAAR Surgical STAA | $1.26B | -6% | +51% | 18% | 45.8× | n/a |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 24.5× | 3.5% |
| Alcon ALC.SW | $37.5B | +22% | -1% | 11% | 21.4× | 12.9% |
| Bausch + Lomb BLCO.TO | $7.20B | +31% | +11% | 9% | 17.3× | 11.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | STAA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.7% | +0.9% | 5th highest of 21 |
| 6-month return | -5.5% | -4.5% | 11th highest of 21 |
| Distance from 52-week high | -29.7% | -35.8% | 8th highest of 21 |
| Revenue growth (TTM) | +51.3% | +14.5% | 2nd highest of 20 |
| Operating margin | 18.0% | 15.3% | 8th highest of 20 |
| Forward P/E | 45.8× | 26.1× | 3rd most expensive of 15 |
| ROIC minus cost of capital | +11.1 pp | +0.2 pp | 6th highest of 20 |
| EV / EBITDA | 15.8× | 11.8× | 3rd most expensive of 6 |
| Net debt / EBITDA | -2.1× | -1.5× | 3rd least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| STAAR Surgical STAA | United States | $1.26B | -6% | +51% | 18% | 45.8× | n/a | n/a |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.27B | -15% | +21% | 16% | 25.2× | 10.8% | +40.3% |
| Alpha Tau Medical DRTS | United States | $1.27B | +61% | n/a | n/a | n/a | n/a | n/a |
| Guangzhou Hexin Instrument 688622.SS | China | $1.26B | +58% | -29% | -74% | n/a | n/a | n/a |
| CLASSYS 214150.KS | South Korea | $1.25B | -54% | +25% | 46% | 12.1× | -8.7% | +34.5% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.24B | -25% | -6% | 18% | 27.0× | 12.7% | -3.5% |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.31B | -51% | +132% | 2% | 130.1× | n/a | n/a |
| PROCEPT BioRobotics PRCT | United States | $1.18B | -19% | +23% | -34% | n/a | n/a | n/a |
| Tandem Diabetes Care TNDM | United States | $1.18B | +9% | +4% | -4% | n/a | n/a | n/a |
| Sansure Biotech 688289.SS | China | $1.36B | -8% | -1% | 1% | 39.0× | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.16B | -18% | +17% | 9% | n/a | 53.9% | +8.6% |
| Alphatec ATEC | United States | $1.15B | -1% | +15% | -3% | 15.0× | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.14B | +6% | +14% | 25% | 33.7× | 10.0% | +8.8% |
| Sonoscape Medical 300633.SZ | China | $1.42B | -8% | +18% | 4% | 36.8× | n/a | n/a |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 36% | 18.2× | 1.5% | +9.9% |
| Nakanishi 7716.T | Japan | $1.42B | +8% | +15% | 19% | 16.3× | 2.2% | +19.7% |
| Ovctek China 300595.SZ | China | $1.42B | -26% | 0% | 28% | 20.8× | 9.9% | +16.5% |
| El.En ELN.MI | Italy | $1.44B | +11% | +3% | 15% | 21.8× | 9.8% | +7.7% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.11B | -27% | -11% | -33% | n/a | n/a | n/a |
| IRadimed IRMD | United States | $1.10B | 0% | +11% | 32% | 36.0× | 19.1% | +21.5% |
| Suzhou Sepax Technologies 688758.SS | China | $1.45B | +19% | +28% | 40% | 50.8× | 24.7% | +23.6% |